Continuing Medical Education On Oncology | Online Oncology CME Courses

Oncology

Search

Filter Content

Results 1 - 66 of 66

Understanding PNH and Other Complement-mediated Hematologic Disorders

Getting to Know PNH

Current and Emerging Treatment Options in PNH

Understanding Myelofibrosis

Risk Stratification in Myelofibrosis Management

Current and Emerging JAK Inhibitors

Treating HCC Cases with Locoregional and Systemic Therapies

Evolving Systemic Treatments for Hepatocellular Carcinoma: Multidisciplinary Strategies

Biomarker-Driven Treatment of Metastatic Colorectal Cancer

Treating & Assessing Treatment Response: AL Amyloidosis

The Advancing Treatment Landscape in Amyloidosis: Are You Ready?

Immune Checkpoint Inhibitors and RCC: Where Are We Now?

Evolving Treatment Options for the Treatment of HCC with Immunotherapy and LDT

CAR T-Cell Therapy Consults: Navigating a New Landscape

Managing Side Effects of Newer Therapies for Acute Lymphoblastic Leukemia (ALL)

Emerging Treatments in Chronic GvHD

Treatment of Ph+ Relapsed/Refractory ALL

Treatment of Ph- Relapsed/Refractory ALL

Identification of Relapsed ALL

9089_nsclc_titleslide

TARGET for NSCLC: Genomic Pathways and Use of EGFR Therapies

Ensuring Effective Care Transitions in Beta Thalassemia

Principles of Management of Chronic GVHD

Diagnosing and Assessing Chronic Graft-versus-Host Disease

Cardiac Amyloidosis: Is It A Zebra or A Horse? Webinar Summary Module

Cardiac Amyloidosis Webinar #4: Treatment of Cardiac Amyloidosis

Cardiac Amyloidosis Webinar #3: Establishing the Correct Diagnosis

Cardiac Amyloidosis Webinar #2: Cardiac Imaging Pearls

Cardiac Amyloidosis Webinar #1: Who Should I be Testing?

Reversing DOACS: Providing Answers to What, Where and How

Reversing DOACS: Recording from Live Session held on July 18, 2021

Conquer the Clot: Addressing VTE in Your Patients with Cancer

9076-0001-263x149

Healthcare Disparities in African Americans With Myeloma

Cancer-Associated Thrombosis: Catheter-related Thrombosis (CRT) VTE

Approach to the Patient With Cancer-associated VTE

Cancer-Associated Thrombosis: Primary Prophylaxis

Palliative Care for mRCC

Salvage Therapies for Metastatic Renal Cell Carcinoma

Is There Still a Role For Cytoreductive Nephrectomy

Management of Rare RCC Histologies

Contemporary Topics in RCC: Tumor Board

Genomics Essentials In Hematologic Malignancies (GENOM)

What's New in Advanced CSCC Care

New Paradigms in the Management of Locally Advanced or Metastatic CSCC

What's New in Advanced CSCC Care

The Evidence So Far: Risk, Referral, and What's New in Advanced CSCC Care

Palliative Embolization

Vertebroplasty and Vertebral Augmentation for Spine Metastases or Pathologic Fractures

Effective Communication With Your Patient and Family

Palliative Ablations of Bone and Soft Tissue Tumors

Palliative Interventional Oncology Podcast Series

Pulmonologists as the Gatekeepers of Precision Medicine

Biosimilars: Applying the Science to Hematology/Oncology Practice

biosims-archmed icon

Top Questions about Biosimilars in Hematology/Oncology

Interchangeability and Pharmacy-Level Substitution

FDA Criteria: Biosimilar Approval, Manufacturing, & Naming

What is the Difference Between a Biosimilar and a Generic?

What is a Biologic?

New Strides in EGFR Inhibition for Non–Small Cell Lung Cancer

Pete - Work-Up of a Patient with Right Upper Lobe Mass and Metastases

Carl - High Suspicion of Lung Cancer: Setting the Stage with a Good Biopsy

Sorting it Out: Biologics, Biosimilars, Small Molecule Drugs, and Generics

Health Care Providers’ Perspectives on Biosimilars: Based in Fact or Not?

Pharmacovigilance and Biosimilars: Any Special Considerations?

Interchangeability and Biosimilars: What will this Mean for Clinical Practice?

Can a Biosimilar be Used for the Same Indications Approved for the Reference Biologic?

Biosimilars: As Safe and Effective as the Reference Product?

Drift and the Manufacturing of Biologics: What is it and Does it Matter?

Biosimilars in Clinical Practice: Interchangeability and Extrapolation